Agilon Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports corporate governance changes at agilon health, inc., a Delaware corporation listed on the NYSE under the symbol AGL. The earliest reported event occurred on June 21, 2023; the director changes became effective June 22, 2023. The filing was signed and dated June 26, 2023.
Key Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating and financial performance metrics.
Material Changes
- Richard Schnall, Clay Richards, and Derek L. Strum resigned from the Board effective June 22, 2023.
- The resignations were not due to disagreements with the Company regarding operations, policies, or practices.
- The resignations supported the transition to a Board with a majority of independent directors, satisfying NYSE director-independence requirements.
- Agilon previously qualified as a controlled company because CD&R Vector Holdings, L.P. held at least 50% of voting power. CD&R ceased holding more than 50% on August 11, 2022, and the Company no longer qualified as a controlled company.
- Silvana Battaglia was appointed as an independent Class I director to fill the vacancy created by Mr. Schnall’s resignation. Her term runs until the 2025 annual meeting, subject to earlier resignation or removal.
- Ms. Battaglia was appointed to the Compensation and Human Capital Committee.
- Effective June 22, 2023, the Compensation and Human Capital, Nominating and Governance, Audit, and Compliance and Quality Committees were reconstituted with independent-director participation as disclosed in the filing.
Compensation, Outlook, and Risks
- Ms. Battaglia received options valued at $185,000 with an exercise price of $16.74, vesting in three equal annual installments beginning on each anniversary of June 22, 2023.
- She also received restricted stock units with an aggregate value of $185,000, prorated for her 2023 service period. The units vest in full one year after grant, subject to continued service.
- The filing contains no financial guidance, operating outlook, management forecast, material contingency, or unusual financial item.
- The principal governance consideration is the Company’s compliance with NYSE director-independence requirements following the loss of controlled-company status.
Important Facts to Verify
- Confirm the effective dates of the three resignations and Ms. Battaglia’s appointment.
- Verify the Board’s current majority-independent composition and committee memberships.
- Review the terms, valuation, exercise price, and vesting schedules of Ms. Battaglia’s equity awards.
- Review Exhibit 99.1, the press release announcing the appointment, for any additional governance commentary.